Patents by Inventor Francis Dodeller

Francis Dodeller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies targeting M-CSF
    Patent number: 10081675
    Abstract: This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: September 25, 2018
    Assignee: MORPHOSYS AG
    Inventors: Francis Dodeller, Robert Rauchenberger
  • ANTIBODIES TARGETING M-CSF
    Publication number: 20180057581
    Abstract: This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.
    Type: Application
    Filed: October 27, 2017
    Publication date: March 1, 2018
    Applicant: MorphoSys AG
    Inventors: Francis Dodeller, Robert Rauchenberger
  • Antibodies targeting M-CSF
    Patent number: 9856316
    Abstract: This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: January 2, 2018
    Assignee: MORPHOSYS AG
    Inventors: Francis Dodeller, Robert Rauchenberger
  • Antibodies Targeting M-CSF
    Publication number: 20160102142
    Abstract: This disclosure generally relates to antibodies or antibody fragments which specifically bind to M-CSF. In particular antibodies and antibody fragments are disclosed which bind to M-CSF and which inhibit binding of M-CSF to the M-CSF receptor with an IC50 of 10 pM or less. The invention also relates to nucleic acids, vectors and host cells capable of expressing the antibodies or fragments thereof of the invention, pharmaceutical compositions comprising the antibodies or fragments thereof and uses of said antibodies or fragments thereof and compositions for treatment of specific diseases.
    Type: Application
    Filed: April 11, 2014
    Publication date: April 14, 2016
    Inventors: Francis Dodeller, Robert Rauchenberger